Longwoods Publishing’s Post

There is a growing interest in #qualityimprovement collaboratives (QICs), even though less remains known about contextual factors that impact collective and local project implementation. A study was undertaken that used the Consolidated Framework for Implementation Research (CFIR) to explore the contextual factors impacting the use of this nationwide QIC in Canada. This study provides insights into contextual factors that impact the implementation of local safety projects involved in a larger QIC, which may serve as a template or #blueprint for #healthcareleaders in their efforts to guide the co-design, implementation and evaluation of safety and QI efforts. Lianne Jeffs, Frances B., Kim Kinder, Maryanne D'Arpino RN, BScN, MScN, CHE, Gina De Souza RN, MScN, CMP, LSSBB Ross Baker Healthcare Excellence Canada https://lnkd.in/g7NF4yvi

Following the final session on 5 November, we have released an updated interactive map summarizing the outputs of all ‘From Theory to Practice: Implementing the EU Health Technology Assessment Regulation’ sessions facilitated by the European Commission. As we get closer to the January 2025 for first phase implementation, it is reassuring to see EU HTAR readiness scores are increasing and local planning is well underway. While we still await detailed insight to local legislation and HTA process adaptations to effectively accommodate JCA outcomes in local decision making, EU HTA bodies are ready for JCA launch and so are we! Get in touch with our Lumanity HTA experts to see how we can help with your own readiness plans! https://buff.ly/4g9RYim #LumanityPerspectives #EUHTA Regulation #HEOR #HTA

🔎 Learn more about HTA through EUCAPA and be ready to make the new European HTA framework a meaningful step towards fair healthcare systems

It was a busy week: the Implementing Act on Joint Clinical Assessment is published! 23 Member States voted in favour, 4 Member States were not represented. A few things that stand out for manufacturers that are worth already mentioning here: "Upon request of the health technology developer, the HTA secretariat shall invite the health technology developer to an assessment scope explanation meeting with the JCA Subgroup." --- previously, this was to be decided by the JCA Subgroup. "The deadline to submit the dossier [...] shall be 100 days from the date of the notification of the first request to the health technology developer." --- previously, this was 90 days. These are 2 out of (frankly, few...) changes following the public consultation. Reflecting back to the webinar Lumanity provided together with Neil Grubert in January and our EU JCA / IRA webinar last week together with Ron Akehurst and Jonathan Kowalski, there are still some challenges to tackle. What are your thoughts? #EUHTA #JCA #EUHTAR #patientaccess

Systematic literature reviews (SLRs) are typically required as part of the health technology assessment (HTA) process, but the focus and mandatory  requirements of SLRs vary by HTA body. Maverex investigated the SLR requirements of eight HTA agencies around the world. Read below to see what we found. Early strategic planning of SLR requirements, including engaging in early scientific advice with HTA agencies, can ensure SLRs fulfil the requirements for multiple HTA bodies in a timely and efficient manner. Contact us today to speak to one of our HTA and SLR experts, or if you would like further information. This research was presented at ISPOR 2024. #SLR #HTA #MarketAccess #TechnologyAppraisal

I’m happy to share that I’ve obtained a new certification: Introduction to ICH - GOOD CLINICAL PRACTICE E6 (R2) from The Global Health Network! #ICHGCP #TGHN #Certificate #Goodclinicalpractice #Clinicalresearch

Looking for expert #JCA advice? Our brand new AI-powered tool is here to provide you with clear, actionable guidance, leveraging curated insights from reliable and up-to-date sources. ✨ Ready to experience smarter, faster support? Try it now and see the difference for yourself! 📩 Contact us at contact@remapconsulting.com to get started, and don’t forget to share your feedback—your suggestions will help us make it even better. #Innovation #AIPoweredSolutions #JCAAdvice #RemapConsulting

✨️ I'm thrilled to share that I’ve completed the Fast Track Training "Health Technology Assessment" course organised by EUCAPA. (#EUCAPA is a joint effort of three organisations dedicated to advancing healthcare for patients through Health Technology Assessment (HTA) training. The consortium includes the European Organisation for Rare Diseases (EURORDIS-Rare Diseases Europe), the #EPF (European Patients' Forum), and #UMIT #TIROL - Private Universität für Gesundheitswissenschaften, Medizinische Informatik und Technik , Austria) 🚀 This EUCAPA program has enriched my understanding of evaluating the medical, social, economic, and ethical implications of healthcare interventions. 📊 If you know anything about me, then you know I love to educate myself, as it empower me to advocate for patient-centered care and rare disease solutions, areas I am passionate about. It also deepens my ability to work with healthcare professionals and stakeholders in making informed decisions that impact patients' lives. 💡 📚 Learning is a continuous journey, and this is one more step toward advancing patient advocacy and engagement through knowledge and collaboration. I look forward to applying these insights in future projects! #HealthTech #HTA #PatientAdvocacy #HealthcareInnovation #LifelongLearning #RareDiseases #MedicalInnovation

Exciting update on EU HTA: First Implementing Act unveiled Today marks an important milestone as the first Implementing Act for the European Regulation on Health Technology Assessment (HTA) has been released and public consultation begins. While maintaining continuity, there are some concessions for industry engagement. Key highlights include: possible involvement of health technology developers (HTDs) in assessment scope development; explanation meetings post-scope design; and provision for data updates both during, and after, the initial JCA process. Stay tuned as our teams at Cencora continue to analyze this information and share more insights soon! Learn more here: https://ow.ly/5Wmi50QM0kj #HTAR #HealthTechnologyAssessment #EuropeanRegulation

Our CEO Fiona Loughlan and GMO Karin Burroughs, MBA, MSc. Burroughs are both dedicated to this industry, and together, sit on a number of committees including the Australian Commission on Safety and Quality in Health Care - Accrediting Agency Working Group (ACSQHC). It is the national health care standards agency for all health services, general practices, pathology and medical imaging providers in Australia. It's responsible for: 🔹 Developing clinical care and quality standards 🔹 Overseeing model national accreditation schemes for healthcare services 🔹 Working with patients, consumers, clinicians, managers, policy makers, and healthcare organizations 🔹 Improving end-of-life care The ACSQHC's accreditation schemes include the Australian Health Service Safety and Quality Accreditation (AHSSQA) Scheme. The AHSSQA Scheme coordinates accreditation processes nationally and sets out the responsibilities of accrediting agencies. The ACSQHC's accreditation process involves: 🔹 Formulating rules for the accreditation scheme 🔹 Approving accrediting agencies and managing their performance 🔹 Ensuring consistent assessments across accrediting agencies 🔹 Evaluating the effectiveness of accreditation schemes It's just another way Fiona and Karin, as industry leaders, demonstrate their expertise, integrity and reputation. #IHCA #SupportingExcellence